

What we claim is: CLAIMS

1. A method of treatment of a disease condition caused by papilloma virus, which comprises:
applying an effective amount of a *Mycobacterium* to the region of infection.
2. The method of claim 1 wherein the papilloma virus is human papilloma virus.
3. The method of claim 2 wherein the disease condition include cutaneous and genital warts in humans.
4. The method of claim 2 wherein the disease condition is external and intraurethral condylomata acuminata in humans.
5. The method of claim 1 wherein said *Mycobacterium* is an attenuated form of a *Mycobacterium* of the tuberculosis complex.
6. The method of claim 5 wherein said attenuated *Mycobacterium* is an attenuated form of *M. bovis*.
7. The method of claim 4 wherein said *Mycobacterium* is Bacillus Calmette-Guerin. (BCG).
8. The method of claim 1 wherein from about 1 to about 30 treatments of time interval from about 1 to about 30 days between treatments of more than one and the individual treatment dosage is from about 1 to about 500 mg of the *Mycobacterium*.
9. The method of claim 1 which is preceded by ablative surgery of the region of infection.

10. The method of claim 9 wherein said ablative surgery is effected by laser.

5
11. The method of claim 1 wherein said *Mycobacterium* is formulated with a keratolytic agent for topical application to the region of infection.

10
12. The method of claim 11 wherein said *Mycobacterium* is formulated with said keratolytic agent as a cream for adherent application to the region of infection.

15
13. The method of claim 7 wherein said BCG is formulated with powdered salicylic acid as an adherent cream for application to the region of infection.

14. The method of claim 13 wherein said salicylic acid is present in an amount of about 0.1 to about 50 wt% of the composition.

20
15. The method of claim 14 wherein said salicylic acid is present in an amount of about 1 to about 10 wt%.


25
16. A therapeutic composition for the treatment of a disease condition caused by papilloma virus, comprising an effective amount of a *Mycobacterium* formulated with a keratolytic agent for topical application to a region of infection.

30
17. The composition of claim 16 wherein said *Mycobacterium* is an attenuated form of a *Mycobacterium* of the tuberculosis complex.


18. The composition of claim 17 wherein the *Mycobacterium* is an attenuated form of *M. bovis*.

- 18 -

~~19. The composition of claim 16 wherein said *Mycobacterium* is Bacillus Calmette-Guerin (BCG).~~

 5 20. The composition of claim 19 wherein said keratolytic agent is powdered salicylic acid.

21. The composition of claim 20 wherein said salicylic acid is present in an amount of from about 0.1 to about 50 wt% of the composition.

 10 22. The composition of claim 21 wherein said salicylic acid is present in an amount of about 1 to about 10 wt%.

15 23. The composition of claim 16 which is formulated as a cream for adherent application to the region of infection.

20 24. The use of a *Mycobacterium* in the manufacture of a medicament for the treatment of infection caused by papilloma virus, particularly human papilloma virus.

25. The use of claim 24 including any application or preparation of the *Mycobacterium*, such as cream, powder, slow-release formulation, inhalation, enema or oral application.